Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an update.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for a change in the marketing license holder of its Cobamamide Capsules. This approval follows a contract signed with Beijing Baiya United Pharmaceutical Research Institute, transferring the marketing authorization holder status and related technical rights to Xinhua Pharmaceutical, enhancing its market position and operational capabilities.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in the People’s Republic of China, focusing on the production and marketing of prescription drugs. The company is involved in the development and commercialization of pharmaceutical products, with a particular emphasis on prescription medications.
Average Trading Volume: 4,872,574
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.4B
For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.